News & Updates

Show Multimedia Only

Investigational nasal spray for dry eye disease scores high in phase II trial

16 Aug 2022

The single-dose nicotinic acetylcholine receptor agonist OC-02, administered as an aqueous nasal spray, helps increase tear production and improve eye dryness in patients with dry eye disease (DED), according to data from the phase II PEARL trial.

Investigational nasal spray for dry eye disease scores high in phase II trial

16 Aug 2022

Rose Bengal PDAT a promising adjunct therapy for infectious keratitis

15 Aug 2022

In patients with infectious keratitis, Rose Bengal (RB) photodynamic antimicrobial therapy (PDAT) mitigates the need for therapeutic penetrating keratoplasty, as shown in a recent study. However, keratoplasty after RB-PDAT may increase the chances of graft survival at 1 year postoperatively.

Rose Bengal PDAT a promising adjunct therapy for infectious keratitis

15 Aug 2022

Original New Drug Application Approvals by US FDA (01 - 15 August 2022)

15 Aug 2022

New drug applications approved by US FDA as of 01 - 15 August 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 August 2022)

15 Aug 2022

Vigorous exercise a risk factor for central serous chorioretinopathy

12 Aug 2022

Frequent, vigorous physical activity can have negative consequences, with a recent study suggesting that this level of activity increases the odds of central serous chorioretinopathy by more than fivefold.

Vigorous exercise a risk factor for central serous chorioretinopathy

12 Aug 2022

$Portable, low-cost refraction device shows promise for first-level assessments$

Portable, low-cost refraction device shows promise for first-level assessments

12 Aug 2022 by

ClickCheck, a portable and low-cost refractive error measurement device, demonstrates a high level of agreement with the standard-practice subjective refraction (SR) in terms of spherical power, according to a recent study. Nevertheless, improvements are needed to yield better cylindrical power evaluations.

Portable, low-cost refraction device shows promise for first-level assessments

12 Aug 2022

$Myopic refractive error carries increased risk of POAG$

Myopic refractive error carries increased risk of POAG

09 Aug 2022

There appears to be a genetic-based association between the presence of myopic refractive error and an increased risk of primary open-angle glaucoma (POAG), according to the results of a Mendelian randomization study.

Myopic refractive error carries increased risk of POAG

09 Aug 2022

Is bevacizumab beneficial for patients undergoing high-risk corneal transplantation?

06 Aug 2022

Treatment with bevacizumab in patients undergoing vascularized high-risk corneal transplantation shows no significant difference in the rate of endothelial rejection at 1 year when compared to placebo, reports a recent study.

Is bevacizumab beneficial for patients undergoing high-risk corneal transplantation?

06 Aug 2022

Polygenic risk score a reliable predictor of high myopia, macular degeneration in Asians

04 Aug 2022 by

Current polygenic risk scores (PRSs) deliver satisfactory predictive capacity for high myopia (HM) and can pinpoint children at high risk to prevent myopia progression to HM, suggests a Singapore study.

Polygenic risk score a reliable predictor of high myopia, macular degeneration in Asians

04 Aug 2022

Dexamethasone eye drops show therapeutic potential in diabetic macular edema

04 Aug 2022

Topical OCS-01, a dexamethasone ophthalmic suspension, appears to be beneficial in the treatment of patients with diabetic macular edema, with the results of a phase II study showing that the drug helps improve central macular thickness.

Dexamethasone eye drops show therapeutic potential in diabetic macular edema

04 Aug 2022

Glucose-lowering medications protect against glaucoma, AMD

29 Jul 2022

While diabetes is a risk factor for cataract, glucose-lowering medications appear to have a protective effect on the risks of open-angle glaucoma (OAG) and age-related macular degeneration (AMD), as shown in a study.

Glucose-lowering medications protect against glaucoma, AMD

29 Jul 2022

News & Updates

Filter by Specialty:

Specialty:

Investigational nasal spray for dry eye disease scores high in phase II trial

Investigational nasal spray for dry eye disease scores high in phase II trial

Rose Bengal PDAT a promising adjunct therapy for infectious keratitis

Rose Bengal PDAT a promising adjunct therapy for infectious keratitis

Original New Drug Application Approvals by US FDA (01 - 15 August 2022)

Original New Drug Application Approvals by US FDA (01 - 15 August 2022)

Vigorous exercise a risk factor for central serous chorioretinopathy

Vigorous exercise a risk factor for central serous chorioretinopathy

Portable, low-cost refraction device shows promise for first-level assessments

Portable, low-cost refraction device shows promise for first-level assessments

Myopic refractive error carries increased risk of POAG

Myopic refractive error carries increased risk of POAG

Is bevacizumab beneficial for patients undergoing high-risk corneal transplantation?

Is bevacizumab beneficial for patients undergoing high-risk corneal transplantation?

Polygenic risk score a reliable predictor of high myopia, macular degeneration in Asians

Polygenic risk score a reliable predictor of high myopia, macular degeneration in Asians

Dexamethasone eye drops show therapeutic potential in diabetic macular edema

Dexamethasone eye drops show therapeutic potential in diabetic macular edema

Glucose-lowering medications protect against glaucoma, AMD

Glucose-lowering medications protect against glaucoma, AMD